MMP-2 expression and correlation with pathology and MRI of glioma

Zhang,Hui; Ma,Yunxia; Wang,Haibao; Xu,Liyan; Yu,Yongqiang

doi:10.3892/ol.2018.9806

MMP-2 expression and correlation with pathology and MRI of glioma

Authors:
- Hui Zhang
- Yunxia Ma
- Haibao Wang
- Liyan Xu
- Yongqiang Yu
View Affiliations

Affiliations: Department of Radiology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China, Department of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China
Published online on: December 6, 2018 https://doi.org/10.3892/ol.2018.9806
Pages: 1826-1832
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The expression of matrix metalloproteinase-2 (MMP-2) in brain glioma and its correlation with patients' clinicopathological characteristics and magnetic resonance imaging (MRI) features were investigated. A total of 104 patients with brain glioma admitted and treated in the First Affiliated Hospital of Anhui Medical University from June 2010 to September 2014 were randomly enrolled. MRI examination was performed before operation. Immunohistochemistry (IHC) was used to detect the expression levels of MMP-2 in brain glioma tissues and paired normal brain tissues after operation and to analyze the associations of MMP-2 expression with the clinicopathological characteristics of brain glioma and survival time of patients. The relationship between MMP-2 expression and preoperative MRI features of glioma was analyzed. The positive rate of MMP-2 expression in brain glioma was 73.08% (76/104), while that in paired normal brain tissues was only 12.5% (13/104), obviously lower than that in brain glioma tissues (P<0.05). The MMP-2 expression in the body of glioma was not related to the patients' sex, age, tumor location and pathological type (P>0.05), but there was a significant correlation with the tumor diameter and pathological grade of the patients (P<0.05). Analysis by Cox model suggested that tumor diameter, pathological grade and MMP-2 were independent prognostic factors for glioma (P<0.05). The overall survival (OS) of patients in the positive MMP-2 expression group was 16.4 months, while the OS in the negative MMP-2 expression group was 20.16 months, and the difference between the two groups was statistically significant (P<0.05). The positive expression of MMP-2 in glioma was closely related to the uniformity of MRI signal for tumor, tumor diameter, severity of peritumoral edema, degree of enhancement and pathological grade of tumor (P<0.05). MMP-2 is highly expressed in brain glioma, and it is a negative factor for prognosis. Therefore, the MRI manifestations of glioma can reflect to some extent the intensity of MMP-2 expression.

View Figures

View References

1	Sanai N and Berger MS: Glioma extent of resection and its impact on patient outcome. Neurosurgery. 62:753–766. 2018. View Article : Google Scholar
2	Park DM and Rich JN: Biology of glioma cancer stem cells. Mol Cells. 28:7–12. 2009. View Article : Google Scholar : PubMed/NCBI
3	Raymond E, Brandes AA, Dittrich C, Fumoleau P, Coudert B, Clement PM, Frenay M, Rampling R, Stupp R, Kros JM, et al: European Organisation for Research and Treatment of Cancer Brain Tumor Group Study: Phase II study of imatinib in patients with recurrent gliomas of various histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol. 26:4659–4665. 2008. View Article : Google Scholar : PubMed/NCBI
4	Huse JT and Holland EC: Targeting brain cancer: Advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer. 10:319–331. 2010. View Article : Google Scholar : PubMed/NCBI
5	Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, Fouse SD, Yamamoto S, Ueda H, Tatsuno K, et al: Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 343:189–193. 2014. View Article : Google Scholar : PubMed/NCBI
6	Han Y, Wu Z, Wu T, Huang Y, Cheng Z, Li X, Sun T, Xie X, Zhou Y and Du Z: Tumor-suppressive function of long noncoding RNA MALAT1 in glioma cells by downregulation of MMP2 and inactivation of ERK/MAPK signaling. Cell Death Dis. 7:e21232016. View Article : Google Scholar : PubMed/NCBI
7	Rahme GJ and Israel MA: Id4 suppresses MMP2-mediated invasion of glioblastoma-derived cells by direct inactivation of Twist1 function. Oncogene. 34:53–62. 2015. View Article : Google Scholar : PubMed/NCBI
8	Liu LY, Man XX, Yao HX and Tan YY: Effects of pheophorbide a- mediated photodynamic therapy on proliferation and metastasis of human prostate cancer cells. Eur Rev Med Pharmacol Sci. 21:5571–5579. 2017.PubMed/NCBI
9	Tabouret E, Boudouresque F, Farina P, Barrié M, Bequet C, Sanson M and Chinot O: MMP2 and MMP9 as candidate biomarkers to monitor bevacizumab therapy in high-grade glioma. Neuro Oncol. 17:1174–1176. 2015. View Article : Google Scholar : PubMed/NCBI
10	Hu LS, Kelm Z, Korfiatis P, Dueck AC, Elrod C, Ellingson BM, Kaufmann TJ, Eschbacher JM, Karis JP, Smith K, et al: Impact of software modeling on the accuracy of perfusion MRI in glioma. AJNR Am J Neuroradiol. 36:2242–2249. 2015. View Article : Google Scholar : PubMed/NCBI
11	Langlois B, Saupe F, Rupp T, Arnold C, van der Heyden M, Orend G and Hussenet T: AngioMatrix, a signature of the tumor angiogenic switch-specific matrisome, correlates with poor prognosis for glioma and colorectal cancer patients. Oncotarget. 5:10529–10545. 2014. View Article : Google Scholar : PubMed/NCBI
12	Piromkraipak P, Sangpairoj K, Tirakotai W, Chaithirayanon K, Unchern S, Supavilai P, Power C and Vivithanaporn P: Cysteinyl leukotriene receptor antagonists inhibit migration, invasion, and expression of MMP-2/9 in human glioblastoma. Cell Mol Neurobiol. 38:559–573. 2018. View Article : Google Scholar : PubMed/NCBI
13	Aroui S, Najlaoui F, Chtourou Y, Meunier AC, Laajimi A, Kenani A and Fetoui H: Naringin inhibits the invasion and migration of human glioblastoma cell via downregulation of MMP-2 and MMP-9 expression and inactivation of p38 signaling pathway. Tumour Biol. 37:3831–3839. 2016. View Article : Google Scholar : PubMed/NCBI
14	Yi GZ, Feng WY, Zhou Q, Liu YW and Qi ST: The impact of MMP-2 and its specific inhibitor TIMP-2 expression on the WHO grade and prognosis of gliomas in Chinese population: A Meta-Analysis. Mol Neurobiol. 54:22–30. 2017. View Article : Google Scholar : PubMed/NCBI
15	Farina P, Tabouret E, Lehmann P, Barrie M, Petrirena G, Campello C, Boucard C, Graillon T, Girard N and Chinot O: Relationship between magnetic resonance imaging characteristics and plasmatic levels of MMP2 and MMP9 in patients with recurrent high-grade gliomas treated by Bevacizumab and Irinotecan. J Neurooncol. 132:433–437. 2017. View Article : Google Scholar : PubMed/NCBI
16	Cho HJ, Park JH, Nam JH, Chang YC, Park B and Hoe HS: Ascochlorin suppresses MMP-2-mediated migration and invasion by targeting FAK and JAK-STAT signaling cascades. J Cell Biochem. 119:300–313. 2018. View Article : Google Scholar : PubMed/NCBI
17	Roomi MW, Kalinovsky T, Rath M and Niedzwiecki A: Modulation of MMP-2 and MMP-9 secretion by cytokines, inducers and inhibitors in human glioblastoma T-98G cells. Oncol Rep. 37:1907–1913. 2017. View Article : Google Scholar : PubMed/NCBI
18	Ramachandran RK, Sørensen MD, Aaberg-Jessen C, Hermansen SK and Kristensen BW: Expression and prognostic impact of matrix metalloproteinase-2 (MMP-2) in astrocytomas. PLoS One. 12:e01722342017. View Article : Google Scholar : PubMed/NCBI
19	Schepkin VD: Sodium MRI of glioma in animal models at ultrahigh magnetic fields. NMR Biomed. 29:175–186. 2016. View Article : Google Scholar : PubMed/NCBI
20	Krivosheya D and Prabhu SS: Combining functional studies with intraoperative MRI in glioma surgery. Neurosurg Clin N Am. 28:487–497. 2017. View Article : Google Scholar : PubMed/NCBI
21	Jain KK, Sahoo P, Tyagi R, Mehta A, Patir R, Vaishya S, Prakash N, Vasudev N and Gupta RK: Prospective glioma grading using single-dose dynamic contrast-enhanced perfusion MRI. Clin Radiol. 70:1128–1135. 2015. View Article : Google Scholar : PubMed/NCBI